Needham Maintains Buy on Viridian Therapeutics, Raises Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has maintained a Buy rating on Viridian Therapeutics and increased the price target from $30 to $38.
September 11, 2024 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger has maintained a Buy rating on Viridian Therapeutics and increased the price target from $30 to $38, indicating a positive outlook for the stock.
The increase in the price target from $30 to $38 by Needham suggests a positive outlook for Viridian Therapeutics. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100